Cargando…
Natural History of Meningioma Development in Mice Reveals: A Synergy of Nf2 and p16 (Ink4a) Mutations
Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity. Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical be...
Autores principales: | Kalamarides, Michel, Stemmer‐Rachamimov, Anat O., Takahashi, Masaya, Han, Zhi‐Yan, Chareyre, Fabrice, Niwa‐Kawakita, Michiko, Black, Peter M., Carroll, Rona S., Giovannini, Marco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253711/ https://www.ncbi.nlm.nih.gov/pubmed/17924978 http://dx.doi.org/10.1111/j.1750-3639.2007.00105.x |
Ejemplares similares
-
PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss
por: Peyre, Matthieu, et al.
Publicado: (2015) -
Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
por: Nunes, Fabio P., et al.
Publicado: (2013) -
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
por: Jordan, Justin T, et al.
Publicado: (2023) -
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
por: Beauchamp, Roberta L., et al.
Publicado: (2015) -
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
por: Shen, Yiping, et al.
Publicado: (2009)